Trial Profile
A multicenter, randomized, double-blind, placebo-controlled, 16 week study of aripiprazole used as dual therapy in the treatment of patients with chronic stable schizophrenia or schizoaffective disorder demonstrating an inadequate response to quetiapine or risperidone monotherapy.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 13 Nov 2013
Price :
$35
*
At a glance
- Drugs Aripiprazole (Primary)
- Indications Schizoaffective disorder; Schizophrenia
- Focus Therapeutic Use
- Sponsors Bristol-Myers Squibb
- 01 Oct 2009 Results published in the Journal of Clinical Psychiatry.
- 14 Dec 2007 Status change from in progress to completed.
- 15 Jun 2007 Status changed from recruiting